Zymeworks Inc. (NYSE:ZYME) Director Ecor1 Capital, Llc Buys 11,958 Shares

Zymeworks Inc. (NYSE:ZYME) Director Ecor1 Capital, Llc bought 11,958 shares of the firm’s stock in a transaction that occurred on Tuesday, December 24th. The shares were acquired at an average price of $14.12 per share, with a total value of $168,846.96. Following the purchase, the director now owns 14,704,239 shares in the company, valued at $207,623,854.68. This trade represents a 0.08 % increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink.

Ecor1 Capital, Llc also recently made the following trade(s):

• On Thursday, December 26th, Ecor1 Capital, Llc bought 16,692 shares of Zymeworks stock. The stock was purchased at an average price of $14.38 per share, with a total value of $240,030.96.

Zymeworks Price Performance

NYSE:ZYME opened at $14.50 on Friday. The business’s 50-day simple moving average is $14.25 and its 200-day simple moving average is $12.00. Zymeworks Inc. has a fifty-two week low of $7.97 and a fifty-two week high of $17.70. The stock has a market capitalization of $998.73 million, a PE ratio of -9.67 and a beta of 1.12.

Zymeworks (NYSE:ZYME) last issued its quarterly earnings data on Thursday, October 31st. The company reported ($0.39) EPS for the quarter, topping analysts’ consensus estimates of ($0.40) by $0.01. The business had revenue of $16.00 million for the quarter, compared to analyst estimates of $17.90 million. Zymeworks had a negative net margin of 182.75% and a negative return on equity of 23.00%. The firm’s quarterly revenue was down 3.1% on a year-over-year basis. During the same period last year, the business posted ($0.41) earnings per share. On average, research analysts expect that Zymeworks Inc. will post -1.43 earnings per share for the current year.

Wall Street Analysts Forecast Growth

ZYME has been the topic of several recent analyst reports. Leerink Partners raised Zymeworks from a “market perform” rating to an “outperform” rating and boosted their target price for the stock from $10.00 to $25.00 in a report on Thursday, November 7th. Leerink Partnrs raised Zymeworks from a “hold” rating to a “strong-buy” rating in a report on Thursday, November 7th. Wells Fargo & Company raised their price objective on shares of Zymeworks from $12.00 to $14.00 and gave the company an “equal weight” rating in a research report on Thursday, December 19th. Stifel Nicolaus upped their price objective on Zymeworks from $21.00 to $28.00 and gave the stock a “buy” rating in a report on Monday, October 28th. Finally, JPMorgan Chase & Co. upgraded shares of Zymeworks from a “neutral” rating to an “overweight” rating and set a $18.00 target price on the stock in a research report on Monday, December 16th. Two equities research analysts have rated the stock with a hold rating, four have given a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $19.17.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently modified their holdings of the company. Bank of New York Mellon Corp lifted its stake in Zymeworks by 5.0% in the 2nd quarter. Bank of New York Mellon Corp now owns 309,703 shares of the company’s stock valued at $2,636,000 after purchasing an additional 14,825 shares during the last quarter. Principal Financial Group Inc. raised its position in shares of Zymeworks by 18.0% in the second quarter. Principal Financial Group Inc. now owns 30,642 shares of the company’s stock valued at $261,000 after purchasing an additional 4,671 shares during the period. BNP PARIBAS ASSET MANAGEMENT Holding S.A. lifted its stake in shares of Zymeworks by 1.2% during the 2nd quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. now owns 1,930,887 shares of the company’s stock worth $16,431,000 after buying an additional 23,173 shares during the last quarter. Rhumbline Advisers boosted its holdings in shares of Zymeworks by 9.0% during the 2nd quarter. Rhumbline Advisers now owns 86,912 shares of the company’s stock worth $740,000 after buying an additional 7,210 shares during the period. Finally, Victory Capital Management Inc. grew its stake in Zymeworks by 23.5% in the 2nd quarter. Victory Capital Management Inc. now owns 58,300 shares of the company’s stock valued at $496,000 after buying an additional 11,100 shares during the last quarter. 92.89% of the stock is owned by institutional investors and hedge funds.

Zymeworks Company Profile

Zymeworks Inc, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes biotherapeutics for the treatment of cancer. The company’s lead product candidates include zanidatamab, a human epidermal growth factor receptor 2 (HER2) that is in Phase 1, Phase 2, and Phase 3 clinical trials, including certain ongoing pivotal clinical trials; and zanidatamab zovodotin, a HER2 -targeted antibody-drug conjugate that is in Phase 2 clinical trial for the treatment of advanced or metastatic HER2-expressing tumors.